{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:00:00Z","timestamp":1783792800524,"version":"3.55.0"},"reference-count":66,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"5","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,14]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n<jats:p>The Rift Valley fever virus (RVFV) MP-12 vaccine is a promising human and veterinary vaccine. Although the vaccine elicited neutralizing antibody (nAb) in human volunteers, the minimal antibody titer that is needed to afford protection is unknown. Therefore, this study was conducted to determine the minimal nAb titer elicited by the RVFV MP-12 vaccine in human volunteers that protected mice against lethal RVFV challenge as a surrogate assessment of the protective efficacy of the vaccine. Among volunteers who were vaccinated with the MP-12 vaccine during a phase II trial, sera with antibody titers of 1:20 collected 5 years post-vaccination (PV), 1:40 titer collected 2 years PV, and 1:80 titer collected 1 year PV was passively transferred to groups of BALB\/c mice. Blood samples were obtained 1 day after passive transfer to determine the RVFV neutralizing nAb titer before challenge with pathogenic RVFV (strain ZH501). Our results indicated that 1 day after passive transfer of the immune sera, an approximate 4-fold reduction in circulating nAb titers was detected in the mice. The presence of RVFV nAb titers in the range of 1:5 to 1:20 were generally protective (75\u2013100% survival). These results suggested that circulating titers of 1:5 or higher offer a high degree of protection by MP-12-elicited antibody in human volunteers. Also, the findings highlighted the value of using the BALB\/c mouse RVFV challenge model as a surrogate for evaluating the protective nAb responses elicited by MP-12 and possible use for evaluating the efficacy of other RVFV vaccine candidates.<\/jats:p>","DOI":"10.4269\/ajtmh.22-0356","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T12:36:50Z","timestamp":1663591010000},"page":"1091-1098","source":"Crossref","is-referenced-by-count":14,"title":["Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease"],"prefix":"10.4269","volume":"107","author":[{"given":"Douglas M.","family":"Watts","sequence":"first","affiliation":[{"name":"Department of Biological Sciences and Border Biomedical Research Center, The University of Texas at El Paso, University of Texas at El Paso, El Paso, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonna L.B.","family":"Westover","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro M.","family":"Palermo","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences and Border Biomedical Research Center, The University of Texas at El Paso, University of Texas at El Paso, El Paso, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Bailey","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morrill","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Bettinger","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences and Border Biomedical Research Center, The University of Texas at El Paso, University of Texas at El Paso, El Paso, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Monath","sequence":"additional","affiliation":[{"name":"Crozet BioPharma LLC, Devens, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darci R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Naval Medical Research Center, Biological Defense Research Directorate, Fort Detrick, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence J.","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Pathology and Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip R.","family":"Pittman","sequence":"additional","affiliation":[{"name":"Department of Clinical Research 2 U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Orbegozo","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences and Border Biomedical Research Center, The University of Texas at El Paso, University of Texas at El Paso, El Paso, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Gowen","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Emerg Infect Dis","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3201\/eid0802.010023","article-title":"An outbreak of Rift Valley fever in northeastern Kenya, 1997\u201398","volume":"8","author":"Woods","year":"2002"},{"key":"b2","series-title":"Vet Res","first-page":"1","article-title":"Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention","volume":"41","author":"Pepin","year":"2010"},{"key":"b3","series-title":"Infect Ecol Epidemiol.","article-title":"A need for One Health approach\u2014lessons learned from outbreaks of Rift Valley fever in Saudi Arabia and Sudan","author":"Hassan","year":"2014"},{"key":"b4","series-title":"Infectious Diseases of Livestock","first-page":"1037","author":"Swanepoel","year":"2004"},{"key":"b5","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"D69","DOI":"10.1016\/j.vaccine.2009.07.046","article-title":"Rift Valley fever vaccines","volume":"27","author":"Ikegami","year":"2009"},{"key":"b6","series-title":"Curr Opin Virol","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.coviro.2012.02.017","article-title":"Breaking the chain: Rift Valley fever virus control via livestock vaccination","volume":"2","author":"Bird","year":"2012"},{"key":"b7","series-title":"Vaccines (Basel)","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/vaccines5030029","article-title":"Current status of Rift Valley fever vaccine development","volume":"5","author":"Faburay","year":"2017"},{"key":"b8","series-title":"Expert Rev Vaccines","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley Fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"Ikegami","year":"2017"},{"key":"b9","series-title":"Vaccine","first-page":"181","article-title":"Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience","volume":"18","author":"Pittman","year":"2000"},{"key":"b10","series-title":"J Immunol","first-page":"660","article-title":"The development of a formalin-killed Rift Valley fever virus vaccine for use in man","volume":"89","author":"Randall","year":"1962"},{"key":"b11","series-title":"J Immunol","first-page":"293","article-title":"Immunization against Rift Valley fever virus. studies on the immunogenicity of lyophilized formalin-inactivated vaccine","volume":"93","author":"Randall","year":"1964"},{"key":"b12","series-title":"Contrib Epidemiol Biostat","first-page":"124","article-title":"Rift Valley fever vaccine for humans","volume":"3","author":"Eddy","year":"1981"},{"key":"b13","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0264-410X(85)90061-1","article-title":"Rift Valley fever virus vaccine trial: Study of neutralizing antibody response in humans","volume":"3","author":"Niklasson","year":"1985"},{"key":"b14","series-title":"Acta Pathol Microbiol Immunol Scand [C]","first-page":"197","article-title":"Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters","volume":"92","author":"Niklasson","year":"1984"},{"key":"b15","series-title":"Contrib Epidemiol Biostat","first-page":"124","article-title":"Rift Valley fever vaccine for humans","volume":"3","author":"Eddy","year":"1981"},{"key":"b16","series-title":"Bull World Health Organ","first-page":"261","article-title":"World Health Organization (WHO) The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from WHO\/FAO meeting","volume":"61","year":"1983"},{"key":"b17","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1016\/j.vaccine.2013.09.029","article-title":"Vaccines against diseases transmitted from animals to humans: a one health paradigm","volume":"31","author":"Monath","year":"2013"},{"key":"b18","series-title":"J Gen Virol","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985"},{"key":"b19","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.vaccine.2015.12.030","article-title":"Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a phase 1 dose escalation and route comparison study in humans","volume":"34","author":"Pittman","year":"2016"},{"key":"b20","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine phase 2 clinical trial: safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"Pittman","year":"2016"},{"key":"b21","series-title":"J Virol","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1128\/JVI.00135-15","article-title":"Rift valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L segments","volume":"89","author":"Ikegami","year":"2015"},{"key":"b22","series-title":"J Gen Virol","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1099\/0022-1317-71-10-2307","article-title":"Generation and transmission of Rift Valley fever viral reassortants by the mosquito Culex pipiens.","volume":"71","author":"Turell","year":"1990"},{"key":"b23","series-title":"Am J Trop Med Hyg","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4269\/ajtmh.1991.44.278","article-title":"Potential for mosquito transmission of attenuated strains of Rift Valley fever virus","volume":"44","author":"Turell","year":"1991"},{"key":"b24","series-title":"Clin Vaccine Immunol","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1128\/CVI.00114-15","article-title":"Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated Rift Valley fever virus vaccine candidate, in sheep","volume":"22","author":"Miller","year":"2015"},{"key":"b25","series-title":"Arch Virol","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF01311021","article-title":"Experimental Rift Valley fever in rhesus macaques","volume":"99","author":"Peters","year":"1988"},{"key":"b26","series-title":"Am J Vet Res","first-page":"1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987"},{"key":"b27","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991"},{"key":"b28","series-title":"Curr Opin Virol","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.coviro.2018.02.001","article-title":"Rift Valley fever vaccines: current and future needs","volume":"29","author":"Dungu","year":"2018"},{"key":"b29","series-title":"Sci Rep","doi-asserted-by":"publisher","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever","volume":"6","author":"Warimwe","year":"2016"},{"key":"b30","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013a"},{"key":"b31","series-title":"NPJ Vaccines","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41541-019-0138-0","article-title":"Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats","volume":"4","author":"Stedman","year":"2019"},{"key":"b32","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in\u00a0vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"Gowen","year":"2007"},{"key":"b33","series-title":"Am J Hyg","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938"},{"key":"b34","series-title":"J Infect Dis","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/infdis\/jir354","article-title":"Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine","volume":"204","author":"Morrill","year":"2011"},{"key":"b35","series-title":"J Infect Dis","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/infdis\/jir249","article-title":"Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus","volume":"204","author":"Morrill","year":"2011"},{"key":"b36","series-title":"Ribavirin: A Broad Spectrum Antiviral Agent","first-page":"169","author":"Stephen","year":"1980"},{"key":"b37","series-title":"Handbook of Zoonoses, Section B Viral","first-page":"125","author":"Peters","year":"1994"},{"key":"b38","series-title":"Virology","first-page":"256","article-title":"The pathogenesis of Rift Valley fever virus in the mouse model","volume":"407","author":"Smith","year":"1994"},{"key":"b39","series-title":"Virology","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.virol.2012.05.012","article-title":"Ultrastructural study of Rift Valley fever virus in the mouse model","volume":"431","author":"Reed","year":"2012"},{"key":"b40","series-title":"Microb Pathog","first-page":"285","article-title":"Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats","volume":"283","author":"Anderson","year":"1987"},{"key":"b41","series-title":"Lancet","first-page":"1216","article-title":"Efficacy of immune plasma in treatment of Argentine hemorrhagic fever and association between treatment and a late neurological syndrome","volume":"2","author":"Maiztegui","year":"1979"},{"key":"b42","series-title":"J Virol","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1128\/JVI.00337-13","article-title":"Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses","volume":"87","author":"Dodd","year":"2013"},{"key":"b43","series-title":"Antiviral Res","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0166-3542(02)00203-6","article-title":". Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control","volume":"57","author":"Sidwell","year":"2003"},{"key":"b44","series-title":"JAMA","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.1997.03550050074036","article-title":"Biological warfare. A historical perspective","volume":"278","author":"Christopher","year":"1997"},{"key":"b45","series-title":"J S Afr Vet Assoc","first-page":"45","article-title":"An inactivated Rift Valley fever vaccine","volume":"48","author":"Barnard","year":"1977"},{"key":"b46","series-title":"Curr Opin Virol","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.coviro.2018.02.001","article-title":"Rift Valley fever vaccines: current and future needs","volume":"29","author":"Dungu","year":"2018"},{"key":"b47","series-title":"J Virol","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1128\/JVI.02095-06","article-title":"Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry","volume":"81","author":"Bird","year":"2007c"},{"key":"b48","series-title":"Am J Trop Med Hyg","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment","volume":"53","author":"Muller","year":"1995"},{"key":"b49","series-title":"Open Virol J","first-page":"8","article-title":"Molecular biology of Rift Valley fever virus","volume":"4","author":"Bouloy","year":"2010"},{"key":"b50","series-title":"Kitasato Arch Exp Med","first-page":"33","article-title":"Induction of virus-inhibiting factor or interferon in mice by strains with different virulence of Rift Valley fever virus","volume":"45","author":"Higashihara","year":"1972"},{"key":"b51","series-title":"Microb Pathog","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0882-4010(88)90096-4","article-title":"Viral determinants of virulence for Rift Valley fever (RVF) in rats","volume":"5","author":"Anderson","year":"1988"},{"key":"b52","series-title":"Rev Infect Dis","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/clinids\/11.Supplement_4.S815","article-title":"Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha","volume":"11","author":"Morrill","year":"1989"},{"key":"b53","series-title":"Arch Virol","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF01311288","article-title":"Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response","volume":"110","author":"Morrill","year":"1990"},{"key":"b54","series-title":"Contrib Epidemiol Biostat","first-page":"21","article-title":"Pathogenesis of Rift Valley fever","volume":"3","author":"Peters","year":"1981"},{"key":"b55","series-title":"Antiviral Res","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0166-3542(86)90024-0","article-title":"Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator","volume":"6","author":"Peters","year":"1986"},{"key":"b56","series-title":"J Virol","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","article-title":"Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs","volume":"75","author":"Bouloy","year":"2001"},{"key":"b57","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immuneresponses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006"},{"key":"b58","series-title":"Epidemiol Infect","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1017\/S0950268808001696","article-title":"An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus","volume":"137","author":"Heise","year":"2009"},{"key":"b59","series-title":"Virology","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.virol.2011.09.023","article-title":"Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection","volume":"422","author":"McElroy","year":"2012"},{"key":"b60","series-title":"Vector Borne Zoonotic Dis","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1089\/vbz.2009.0205","article-title":"Experimental infection of young adult European breed sheep with Rift Valley fever virus field isolates","volume":"10","author":"Busquets","year":"2010"},{"key":"b61","series-title":"PLoS Negl Trop Dis","doi-asserted-by":"publisher","first-page":"e1623","DOI":"10.1371\/journal.pntd.0001623","article-title":"Innate immune response to Rift Valley fever virus in goats","volume":"6","author":"Nfon","year":"2012"},{"key":"b62","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1016\/j.vaccine.2011.04.043","article-title":"A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(\u2212\/\u2212) mice upon lethal virus challenge","volume":"29","author":"Boshra","year":"2011"},{"key":"b63","series-title":"Vaccines (Basel)","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/vaccines8010082","article-title":"MVA vectored vaccines encoding Rift Valley fever virus glycoproteins protect mice against lethal challenge in the absence of neutralizing antibody responses","volume":"8","author":"Lopez-Gil","year":"2020"},{"key":"b64","series-title":"J Virol","first-page":"e01662","article-title":"Peripheral blood biomarkers of disease outcome in a monkey model of Rift Valley fever encephalitis","volume":"92","author":"Wonderlich","year":"2018"},{"key":"b65","series-title":"Curr Opin Immunol","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0952-7915(00)00241-7","article-title":"NK cells and NKT cells in innate defense against viral infections","volume":"13","author":"Biron","year":"2001"},{"key":"b66","series-title":"J Interferon Res","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1089\/jir.1991.11.297","article-title":"Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey","volume":"11","author":"Morrill","year":"1991"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/107\/5\/article-p1091.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/107\/5\/article-p1091.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/107\/5\/article-p1091.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T17:08:18Z","timestamp":1668618498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/107\/5\/article-p1091.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":66,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.22-0356","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]}}}